52 related articles for article (PubMed ID: 7736870)
1. Nuclear DNA-Content in Mesenchymal Lesions in Dogs: Its Value as Marker of Malignancy and Extent of Genomic Instability.
Boerkamp KM; Rutteman GR; Kik MJ; Kirpensteijn J; Schulze C; Grinwis GC
Cancers (Basel); 2012 Dec; 4(4):1300-17. PubMed ID: 24213507
[TBL] [Abstract][Full Text] [Related]
2. Metastatic potential of an aneurysmal bone cyst.
van de Luijtgaarden AC; Veth RP; Slootweg PJ; Wijers-Koster PM; Schultze Kool LJ; Bovee JV; van der Graaf WT
Virchows Arch; 2009 Nov; 455(5):455-9. PubMed ID: 19838726
[TBL] [Abstract][Full Text] [Related]
3. The clinical value of flow cytometric DNA content analysis in patients with soft tissue sarcomas.
Samur M; Pamir A; Akbulut H; Erekul S; Sağlik Y; Yildiz Y; Dinçol D; Içli F
Sarcoma; 1999; 3(3-4):171-5. PubMed ID: 18521281
[TBL] [Abstract][Full Text] [Related]
4. Relationship between histologic grade and cytofluorometric cellular DNA and RNA content in primary bone tumors.
Takeshita H; Kusuzaki K; Kuzuhara A; Tsuji Y; Ashihara T; Gebhardt MC; Mankin HJ; Springfield DS; Hirasawa Y
Anticancer Res; 2001; 21(2B):1271-7. PubMed ID: 11396198
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of cytofluorometric DNA ploidy analysis in distinguishing benign cartilaginous tumors from chondrosarcomas.
Kusuzaki K; Murata H; Takeshita H; Hirata M; Hashiguchi S; Tsuji Y; Nakamura S; Ashihara T; Hirasawa Y
Mod Pathol; 1999 Sep; 12(9):863-72. PubMed ID: 10496594
[TBL] [Abstract][Full Text] [Related]
6. Flow cytometric determination of DNA content in malignant and benign bone tumours.
Heliö H; Karaharju E; Nordling S
Cytometry; 1985 Mar; 6(2):165-71. PubMed ID: 3979218
[TBL] [Abstract][Full Text] [Related]
7. Multiparameter flow cytometric analysis of neoplasms of the central nervous system: correlation of nuclear antigen p105 and DNA content with clinical behavior.
Appley AJ; Fitzgibbons PL; Chandrasoma PT; Hinton DR; Apuzzo ML
Neurosurgery; 1990 Jul; 27(1):83-96. PubMed ID: 2377285
[TBL] [Abstract][Full Text] [Related]
8. Bivariate RNA and DNA content analysis in breast carcinoma: biological significance of RNA content.
El-Naggar AK; Kemp BL; Sneige N; Hurr KG; Steck K; Tu ZN; Fritsche HA; Singletary SE; Balch CM
Clin Cancer Res; 1996 Feb; 2(2):419-26. PubMed ID: 9816186
[TBL] [Abstract][Full Text] [Related]
9. DNA and RNA content analysis by flow cytometry in the pathobiologic assessment of bone tumors.
el-Naggar AK; Hurr K; Tu ZN; Teague K; Raymond KA; Ayala AG; Murray J
Cytometry; 1995 Mar; 19(3):256-62. PubMed ID: 7736870
[TBL] [Abstract][Full Text] [Related]
10. Flow cytometry in clinical oncology: cell cycle and DNA ploidy in assessing tumor behavior.
Czerniak B; Darzynkiewicz Z; Herz F; Wersto RP; Koss LG
Mater Med Pol; 1989; 21(1):3-9. PubMed ID: 2699343
[TBL] [Abstract][Full Text] [Related]
11. Oncology applications of flow cytometry.
Huh YO; Huck L
Clin Lab Sci; 1992; 5(1):25-7. PubMed ID: 10147718
[TBL] [Abstract][Full Text] [Related]
12. Clinical applications of flow cytometry.
Raber MN
Oncology (Williston Park); 1988 Mar; 2(3):35-43, 47. PubMed ID: 3079323
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
